Effects of Lebrikizumab on Post-Inflammatory Hyperpigmentation in Skin of Color

Following the release of new findings presented at the Revolutionizing Atopic Dermatitis (RAD) Conference on the impact of of lebrikizumab (Ebglyss) on atopic dermatitis in adult and adolescent patients with skin of color, the HCPLive team spoke with Andrew Alexis, MD, MPH, ADmirable investigator, professor of clinical dermatology, and vice-chair for diversity and inclusion at Weill Cornell Medicine.

During the 90-participant, phase 3b ADmirable study, those included had Fitzpatrick skin phototypes IV, V, or VI and self-identified as a race other than White. The trial’s primary efficacy measure had been 75% or greater improvement in the Eczema Area and Severity Index (EASI) at the 16-week mark and, in secondary and exploratory outcomes, Alexis and coauthors had looked at the recently developed PDCA Derm scale, a measure of post-inflammatory hyper- and hypopigmentation and safety data.

Alexis spoke with HCPLive about the PDCA-Derm findings that had indicated improvement in post-inflammatory hyperpigmentation in nearly 2-thirds of patients. He highlighted the significance of these findings and how it aligns with what clinicians should consider when addressing pigmentary sequelae in patients of color.

Alexis has reported advisory/consulting fees from companies including Lilly.

References

1. Alexis A, Moiin A, Waibel J, et al. Efficacy and safety of lebrikizumab in adult and adolescent patients with skin of color and moderate-to-severe atopic dermatitis: final 24-wWeek results from the phase 3b, open-label ADmirable study. Presented at: 2025 Revolutionizing Atopic Dermatitis (RAD) Conference; June 6-7, 2025; Nashville, TN.

2. FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis. September 13, 2024. Accessed June 18, 2025. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-ebglysstm-lebrikizumab-lbkz-adults-and.